Drug Trial Radar · NCT06172322
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
42
Planned (sponsor's estimate)
Start
Dec 28, 2023
Primary completion
Apr 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Nanjing Chia-tai Tianqing PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.
Conditions
- HR Positive/HER-2 Negative Breast Cancer
Interventions
NTQ1062 with FulvestrantDrug
Drug: NTQ1062 tablet(s) ,PO,QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment). Drug: Fulvestrant Injection 500mg in a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: First treatment cycle ( 28 days)
- Recommended phase 2 dose (RP2D)Time frame: Through study completion, an average of 1 year
- Adverse eventsTime frame: Through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.